Decreasing pfmdr1 copy number suggests that Plasmodium falciparum in Western Cambodia is regaining in vitro susceptibility to mefloquine.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Dihydroartemisinin-piperaquine is the current frontline artemisinin combination therapy (ACT) for Plasmodium falciparum malaria in Cambodia but is now failing in several western provinces. To investigate artesunate plus mefloquine (AS+MQ) as a replacement ACT, we measured the prevalence of multiple pfmdr1 copies--a molecular marker for MQ resistance--in 844 P. falciparum clinical isolates collected in 2008 to 2013. The pfmdr1 copy number is decreasing in Western Cambodia, suggesting that P. falciparum is regaining in vitro susceptibility to MQ.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Antimicrob. Agents Chemother.

Title: Antimicrobial agents and chemotherapy

ISSN (Electronic): 1098-6596

ISSN (Print): 0066-4804

Publication date (Electronic): May 2015

Volume: 59

Issue: 5

Affiliations

[1 ] Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.

[2 ] National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia.

[3 ] Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA rfairhurst@niaid.nih.gov.

Article

Publisher Item ID: AAC.05163-14

DOI: 10.1128/AAC.05163-14

PubMed ID: 25712365

SO-VID: 6fe89dd2-31ff-465e-b732-f119e918feca

History

Data availability:

Comments

Comment on this article

scite_

Cited by 17

See all cited by